uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
163.41 56.70 85.48 216.85
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(106.77) (26.82) (17.74) (208.28)
P/B ratio
9.42 6.87 6.92 14.93
Price to Tangible BV
12.85 18.81 13.66 26.42
EV/Sales
123.14 27.50 50.40 176.59
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(14.30) (2.89) (4.56) (18.15)
EV/FCF
(14.05) (2.85) (4.49) (17.85)
Quick Ratio
9.79 9.97 9.99 6.94
Current Ratio
10.01 10.40 10.43 7.12
Net Debt/EBITDA
16.07 12.55 11.90 13.55
Debt/Assets
5.09% 6.41% 6.02% 5.84%
Debt/Equity
0.15 0.33 0.25 0.23
Asset Turnover
0.02 0.03 0.02 0.02
Operating CF/Net income
0.35 0.71 2.09 0.20
Capex/Depreciation
(0.10) (0.05) (0.04) 0.02
Interest Coverage
(3.63) (3.26) (3.51) (3.05)
Research and Development Expense of Revenue
581.48% 819.09% 624.71% 928.56%
Selling, General and Administrative Expense of Revenue
297.33% 563.39% 388.11% 525.21%
Intangible Assets out of Total Assets
0.09 0.12 0.12 0.11
Share Based Compensation of Revenue
85.88% 142.90% 83.75% 95.16%
Graham Net Nets
0.06 (0.01) 0.02 0.02
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(8.71%) (21.28%) (14.42%) (7.52%)
Free Cash Flow Yield
(5.36%) (17.04%) (13.13%) (4.56%)
Revenue per Share
0.09 0.06 0.10 0.06
Operating CF per Share
(0.43) (0.61) (1.35) (0.28)
Capex per Share
(0.01) 0.00 0.00 0.00
Free Cash Flow per Share
(0.44) (0.61) (1.35) (0.28)
Cash per Share
12.23 9.35 10.83 11.86
Shareholders Equity per Share
4.89 2.38 3.46 3.91
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
4.89 2.38 3.46 3.91
Free Cash Flow
(29.05) (38.38) (77.69) (16.33)
Working Capital
750.92 556.55 593.07 615.56
Capital Expenditures
(0.47) (0.14) (0.12) 0.07
Net Current Asset Value
173.22 (13.62) 29.98 56.56
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.08 0.04 0.02 (0.02)
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
5.69 3.04 5.87 4.60
Average Payables
5.26 4.83 6.20 5.83
Average Assets
785.00 692.05 690.72 767.09
Average Common Equity
160.02 91.51 96.07 142.28

Fold the line items

Columns are period end dates